📊 VRTX Key Takeaways
Is Vertex Pharmaceuticals Inc. / Ma (VRTX) a Good Investment?
Vertex Pharmaceuticals demonstrates exceptional financial health with exceptional profitability metrics (32.9% net margin, 34.8% operating margin) and robust organic growth of 8.9% revenue YoY despite massive earnings acceleration (838% net income growth). The company combines fortress-like balance sheet strength (0.01x debt/equity, 2.90x current ratio) with exceptional cash generation (3.2B free cash flow, 26.6% FCF margin) providing substantial financial flexibility for R&D investment and shareholder returns.
Vertex Pharmaceuticals shows high-quality fundamentals with strong operating profitability, excellent free cash flow generation, and an exceptionally conservative balance sheet. Revenue growth remains solid, while margins and returns on capital are strong, but the extreme year-over-year jump in net income suggests some earnings volatility or prior-period distortion that should be monitored for sustainability.
Why Buy Vertex Pharmaceuticals Inc. / Ma Stock? VRTX Key Strengths
- Exceptional profitability with 32.9% net margin and 34.8% operating margin indicating pricing power and operational efficiency in pharmaceuticals
- Outstanding cash generation with 3.2B free cash flow and 26.6% FCF margin supporting sustainable business model
- Conservative balance sheet with minimal leverage (0.01x debt/equity) and 5.1B cash providing strategic flexibility
- Strong liquidity metrics with 2.90x current ratio and 71.8x interest coverage indicating minimal financial stress
- Solid 21.2% ROE and 15.4% ROA demonstrating efficient capital deployment
- Consistent organic revenue growth of 8.9% YoY in mature pharmaceutical market
- High profitability with 34.8% operating margin and 32.9% net margin
- Very strong financial health with 2.90x current ratio, 0.01x debt/equity, and $5.08B in cash
- Robust cash generation with $3.19B in free cash flow and 26.6% FCF margin
VRTX Stock Risks: Vertex Pharmaceuticals Inc. / Ma Investment Risks
- Extraordinary 838% net income growth YoY appears anomalous and may reflect one-time gains or accounting adjustments rather than sustainable operational performance
- Pharmaceutical sector faces regulatory risks, patent expirations, and drug development uncertainties affecting future revenue streams
- High insider Form 4 activity (66 filings in 90 days) warrants monitoring for potential signaling of executive sentiment
- Gross margin data unavailable limits full profitability assessment and visibility into cost structure
- Net income growth far exceeded revenue growth, which may indicate non-recurring items or difficult comparability
- Revenue growth of 8.9% is healthy but not exceptional for a pharmaceutical company facing pipeline and product-cycle risk
- Gross margin data is unavailable, limiting visibility into cost structure resilience
Key Metrics to Watch
- Revenue growth trajectory and organic growth sustainability beyond the 8.9% YoY baseline
- Net income normalization pattern to assess if 838% growth is sustainable or anomalous
- Free cash flow generation maintenance and capital allocation decisions
- Operating margin stability amid potential R&D investment cycles
- Debt/Equity ratio given cash-generative nature and potential M&A or acquisition opportunities
- Sustainability of operating margin and net income versus more modest revenue growth
- Free cash flow conversion and revenue growth trajectory in upcoming filings
Vertex Pharmaceuticals Inc. / Ma (VRTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.90x current ratio provides a solid financial cushion.
VRTX Profit Margin, ROE & Profitability Analysis
VRTX vs Healthcare Sector: How Vertex Pharmaceuticals Inc. / Ma Compares
How Vertex Pharmaceuticals Inc. / Ma compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vertex Pharmaceuticals Inc. / Ma Stock Overvalued? VRTX Valuation Analysis 2026
Based on fundamental analysis, Vertex Pharmaceuticals Inc. / Ma appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vertex Pharmaceuticals Inc. / Ma Balance Sheet: VRTX Debt, Cash & Liquidity
VRTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vertex Pharmaceuticals Inc. / Ma's revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $13.89 reflects profitable operations.
VRTX Revenue Growth, EPS Growth & YoY Performance
VRTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.8B | $1.0B | $4.01 |
| Q2 2025 | $2.6B | $1.0B | $3.99 |
| Q1 2025 | $2.7B | $646.3M | $2.49 |
| Q3 2024 | $2.5B | $1.0B | $3.97 |
| Q2 2024 | $2.5B | $915.7M | $3.52 |
| Q1 2024 | $2.4B | $699.8M | $2.69 |
| Q3 2023 | $2.3B | $930.5M | $3.59 |
| Q2 2023 | $2.2B | $810.5M | $3.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vertex Pharmaceuticals Inc. / Ma Dividends, Buybacks & Capital Allocation
VRTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vertex Pharmaceuticals Inc. / Ma (CIK: 0000875320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VRTX
What is the AI rating for VRTX?
Vertex Pharmaceuticals Inc. / Ma (VRTX) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are VRTX's key strengths?
Claude: Exceptional profitability with 32.9% net margin and 34.8% operating margin indicating pricing power and operational efficiency in pharmaceuticals. Outstanding cash generation with 3.2B free cash flow and 26.6% FCF margin supporting sustainable business model. ChatGPT: High profitability with 34.8% operating margin and 32.9% net margin. Very strong financial health with 2.90x current ratio, 0.01x debt/equity, and $5.08B in cash.
What are the risks of investing in VRTX?
Claude: Extraordinary 838% net income growth YoY appears anomalous and may reflect one-time gains or accounting adjustments rather than sustainable operational performance. Pharmaceutical sector faces regulatory risks, patent expirations, and drug development uncertainties affecting future revenue streams. ChatGPT: Net income growth far exceeded revenue growth, which may indicate non-recurring items or difficult comparability. Revenue growth of 8.9% is healthy but not exceptional for a pharmaceutical company facing pipeline and product-cycle risk.
What is VRTX's revenue and growth?
Vertex Pharmaceuticals Inc. / Ma reported revenue of $12.0B.
Does VRTX pay dividends?
Vertex Pharmaceuticals Inc. / Ma does not currently pay dividends.
Where can I find VRTX SEC filings?
Official SEC filings for Vertex Pharmaceuticals Inc. / Ma (CIK: 0000875320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VRTX's EPS?
Vertex Pharmaceuticals Inc. / Ma has a diluted EPS of $15.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VRTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vertex Pharmaceuticals Inc. / Ma has a BUY rating with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is VRTX stock overvalued or undervalued?
Valuation metrics for VRTX: ROE of 21.2% (sector avg: 15%), net margin of 32.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy VRTX stock in 2026?
Our dual AI analysis gives Vertex Pharmaceuticals Inc. / Ma a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VRTX's free cash flow?
Vertex Pharmaceuticals Inc. / Ma's operating cash flow is $3.6B, with capital expenditures of $437.6M. FCF margin is 26.6%.
How does VRTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 32.9% (avg: 12%), ROE 21.2% (avg: 15%), current ratio 2.90 (avg: 2).